Breaking AI & Tech News Analyzed

Researchers from Stanford, Oxford and UC San Diego have demonstrated a proof‑of‑concept wearable ultrasound patch that can monitor a baby’s heart rate and blood flow continuously, aiming to reduce false alarms and missed complications in pregnancy.A Patch That Turns Ultrasound Into a Wearable SensorThe device, dubbed UPatch, adheres to the abdomen and remains operational for hours, capturing real‑time images of the foetus and umbilical cord. Unlike intermittent hospital scans, the patch records a continuous stream of data, allowing clinicians to establish a personal baseline for each pregnancy and spot deviations instantly.Trial Results Show Near‑Parity With Conventional ScansIn a study published in Nature Biotechnology, the team evaluated the patch in two cohorts:62 pregnant participants – single‑time‑point blood‑flow measurements from UPatch matched those from standard handheld ultrasound.52 women – continuous monitoring revealed dynamic fluctuations in fetal blood flow that brief scans would miss.A pre‑eclamptic case where UPatch detected severe intra‑uterine growth restriction, prompting a timely caesarean delivery and preventing stillbirth.Lead author Tom Park highlighted that the technology captures transient changes without over‑diagnosing, addressing a key limitation of current intermittent methods.Potential Shift in Prenatal Care and Global HealthSenior author Prof Sheng Xu emphasized that continuous monitoring could become a routine part of prenatal visits, especially in low‑resource settings where access to skilled sonographers is limited. Dr Antoniya Georgieva noted the broader impact: reducing stillbirth rates, providing richer data for research, and enabling earlier interventions for conditions like pre‑eclampsia.Roadmap Toward a Fully Wireless Home‑Use SystemThe current prototype is tethered to external electronics for placement, but the team is already engineering a wireless version that patients could wear during daily activities and at home. Their long‑term vision is a seamless, battery‑efficient system that integrates with tele‑health platforms, delivering real‑time alerts to clinicians wherever the mother is.

Study Shows Fetal Exposure to Vegetable Flavours Influences Post‑Birth PreferencesThe research team gave pregnant volunteers powdered kale or carrot capsules during the third trimester and later measured their children’s facial reactions to the same smells. Reactions were recorded via ultrasound before birth, repeated at three weeks, and again when the children were about three years old.Methodology: Kale and Carrot Powder Capsules Administered to Expectant MothersParticipants were asked to swallow a capsule each day containing either kale or carrot powder. The study avoided large volumes of juice, which many volunteers found unpalatable, opting for a low‑cost capsule format.Capsules administered in late pregnancy (around 32 weeks gestation).Initial chemosensory response captured with ultrasound imaging.Follow‑up assessments at 3 weeks and 3 years post‑birth.Sample Size and Observed Reactions Reveal Early Flavor MemoryAlthough the cohort was modest, the findings were consistent:12 children were observed at age three.Infants exposed to carrot powder smiled when presented with a carrot scent and grimaced at kale, and vice‑versa for the kale group.The same preference pattern was evident in the ultrasound scans before birth.These results suggest that flavour exposure in utero can create a durable chemosensory memory.Potential Public‑Health Benefits of Early Dietary ConditioningIf replicated on a larger scale, the approach could offer a low‑cost strategy for improving population nutrition:Reducing childhood resistance to vegetables may lower long‑term risks of obesity and diet‑related diseases.Capsules are inexpensive and could be integrated into routine prenatal supplements.The concept is adaptable to different cultural diets, as noted by the researchers’ interest in fish‑rich Japanese diets.Next Steps: Larger Trials and Cross‑Cultural ApplicationsThe authors acknowledge the need for a bigger, funded study to confirm the effect across diverse populations. Future research aims to:Expand the sample size to hundreds of mother‑child pairs.Test additional flavours and odourants, including artificial sweeteners.Explore policy pathways for incorporating flavour‑exposure capsules into prenatal care guidelines.Published in Developmental Psychobiology, the paper titled “Do Human Fetuses Form Long‑Lasting Chemosensory Memories?” opens a new avenue for early nutritional interventions.

FDA Clearance Marks a Milestone for BioticsAI's Ultrasound AI CopilotRobhy Bustami, co‑founder and CEO of BioticsAI, announced that the company obtained FDA approval in January 2026, unlocking the ability to launch its fetal‑abnormality detection system in clinical settings.From Scrappy Prototype to Regulatory SuccessThe team built a functional prototype for under $100,000, an unusually low cost for a medical‑device startup. That early version helped them win TechCrunch Startup Battlefield 2023, providing visibility and credibility that accelerated investor interest.Prototype cost: $100kTechCrunch Battlefield win: 2023FDA approval received: January 2026Financial and Timeline Metrics Behind the ClearanceWhile the article does not disclose full fundraising numbers, the rapid prototype and battlefield win suggest a capital‑efficient path. Early regulatory engagement—pre‑submission meetings with the FDA— reduced uncertainty and compressed the typical multi‑year approval timeline.Early regulator meetings: pre‑submission phaseTypical FDA device timeline: 18‑36 months (compressed by early alignment)Why FDA Approval Shifts the AI‑Healthcare LandscapeGaining clearance validates the technical approach and signals to hospitals that the product meets rigorous safety standards. It also demonstrates a repeatable model for other AI‑driven diagnostics, encouraging more founders to embed regulatory strategy from day one.Creates a trusted entry point for hospital adoptionSets a precedent for AI‑based fetal imaging toolsHighlights the need for cross‑functional teams (engineers, clinicians, regulators)Looking Ahead: Expansion Beyond ObstetricsWith the FDA hurdle cleared, BioticsAI plans to deploy its technology across obstetric units and later broaden into other reproductive‑health applications. The founder emphasizes continued data collection, partnership growth, and potential international regulatory filings as the next growth levers.Phase 1: Hospital rollout in obstetrics (2026‑2027)Phase 2: Expansion into broader reproductive health diagnostics (2028+)Long‑term goal: Global market penetration with localized regulatory approvals

The Journey from Prototype to ClearanceBuilding a medical device is fundamentally different from standard software development. This week on Build Mode, host Isabelle Johannessen sat down with Robhy Bustami, co-founder and CEO of BioticsAI, to discuss the arduous path from a $100,000 prototype to FDA clearance. Bustami, a Startup Battlefield winner, detailed how his team is building an AI copilot for ultrasound designed to detect fetal abnormalities. The conversation revealed that the traditional startup mantra of 'move fast and break things' is obsolete in the medical sector, replaced by a necessity for extreme precision and coordination.Market Validation and Resource AllocationThe episode provides a strategic look at the 'data' driving medtech success. BioticsAI's recognition as a Startup Battlefield winner serves as a key validation of their technology's potential. However, Bustami emphasized that the primary data point for founders is not just market traction, but the successful navigation of complex regulatory pathways. This requires a significant reallocation of resources—shifting focus from rapid feature deployment to ensuring safety, reliability, and compliance with FDA standards.Shifting the MedTech CultureThe core impact of this discussion lies in the cultural shift it highlights for the industry. As timelines for FDA approval remain uncertain, the ability to maintain team morale and investor confidence becomes a critical operational metric. Bustami noted that building in a regulated industry requires a foundation of trust rather than speed. This signals a broader trend where medtech startups must balance the pressure of hyper-growth with the ethical and legal responsibilities of patient safety.The Future of AI in Healthcare RegulationLooking ahead, the medtech landscape will likely see a consolidation of companies that prioritize long-term compliance over short-term hype. As more AI copilots enter the market, the winners will be those founders who master the art of 'slow and steady' innovation. The next wave of medical breakthroughs will depend not just on algorithmic superiority, but on the ability to build sustainable organizations capable of weathering the regulatory storm.

The Challenges of FDA Approval Surviving the long road to FDA approval isn’t just about building great technology — it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. Lessons from BioticsAI This week on Build Mode, Isabelle Johannessen sits down with Robhy Bustami, co-founder and CEO of BioticsAI, a Startup Battlefield-winning company building an AI copilot for ultrasound to help detect fetal abnormalities. From a $100,000 prototype to FDA clearance, Bustami shares what it actually takes to build in one of the most regulated industries in the world. Building a Medtech Startup In this episode, they break down what it really looks like to build a medtech startup, including where you can’t “move fast and break things” and that every milestone takes time, coordination, and trust. Key Takeaways Team motivation is crucial during the long FDA approval process Finding the right investors is essential for medtech startups Adaptability is key when dealing with uncertain timelines Future Outlook As the medtech industry continues to evolve, startups like BioticsAI will play a critical role in shaping the future of healthcare technology. With the right approach and mindset, these companies can overcome the challenges of FDA approval and make a lasting impact.

Pet owners are facing MRI bills that dwarf those for comparable human scans. A recent quote of £1,500 for a dog’s MRI contrasts with a typical private‑hospital price of £700 for a person, highlighting a stark disparity. Industry data from NimbleFins shows the average cost of a dog MRI in 2025 was £3,789, with cats at £3,161 and rabbits around £2,500. By comparison, WeCovr estimates a full‑body human MRI at £1,500‑£2,500. Even the lower end of these ranges exceeds many veterinary quotes, confirming that animal scans are a more expensive business. VAT adds a further 20% surcharge on veterinary services, a tax not applied to most private hospital care. On a £1,500 bill, roughly £250 goes to HMRC, inflating the final amount. According to Rob Williams, president of the British Veterinary Association, the cost structure is fundamentally different. Animals must be anaesthetised for MRI, CT or X‑ray procedures, which requires a dedicated anaesthetic monitor and a technician to operate the scanner. Williams estimates that anaesthesia accounts for 25‑40% of the total price. The same high‑end scanners used in human hospitals are installed in veterinary practices, but utilisation rates are far lower. A typical vet may perform only one or two scans per day, whereas a hospital runs the machine continuously, spreading installation, servicing and energy costs over many more cases. This lack of economies of scale forces vets to charge more per scan. Additional overhead comes from the need to outsource image interpretation. While hospital radiographers read scans in‑house, vets often send images to external specialists, creating another cost layer absent in human care. The price issue has attracted regulatory scrutiny. A two‑and‑a‑half‑year CMA investigation found that vet service fees rose 63% between 2016 and 2023, outpacing general inflation. The report highlighted reduced competition due to chain consolidation and opaque pricing. In response, the CMA now requires practices to publish prices and provide written estimates for any treatment exceeding £500 (including VAT). This aims to give owners the chance to compare offers before committing to expensive procedures such as MRIs. Price‑comparison platform Vet Fair founder Richard Wilkinson reports price variations of 100‑150% between neighbouring practices for the same service. His data also show that ultrasounds from large chains cost 57% more than those from independent clinics. While the CMA reforms may not immediately lower fees, they promise greater transparency, enabling pet owners to make informed decisions and avoid overpaying for high‑tech diagnostics.

Mayor Claudia Kalisch, vice‑president of the German Federation of Cities and leader of the Green‑party city of Lüneburg, announced a push for a nationwide ban on night‑time use of robotic lawnmowers. The proposal aims to curb injuries and deaths among hedgehogs and other small nocturnal animals that frequent residential gardens after dark.Recent research has highlighted that the fast‑moving blades of autonomous mowers pose a hidden danger to wildlife active between dusk and dawn. Hedgehogs, which often curl into a ball when threatened, are especially difficult for mower sensors to detect.Kalisch told the Funke newspaper group that urban green spaces have become critical refuges as development and intensive agriculture shrink natural habitats. She noted that petitions urging the ban have amassed tens of thousands of signatures earlier this year, reflecting broad public concern.In addition to legislative pressure, the mayor called on manufacturers to develop hedgehog‑friendly technology. She emphasized that industry responsibility is essential for protecting biodiversity and improving city life quality.The European red‑list classifies hedgehogs as "near threatened" since 2024, after a documented 30% population decline over the past decade. Beyond mower hazards, motorised leaf blowers, vacuums, and vehicle collisions—responsible for up to one in three fatalities—exacerbate the species’ decline across Europe.Scientists at the University of Oxford, in collaboration with Danish colleagues, recently demonstrated that hedgehogs can hear high‑frequency ultrasound, opening the possibility of sonic road repellers to deter them from dangerous areas. The same team has produced 3D‑printed, crash‑test dummy hedgehogs to work with manufacturers on a future certification scheme for "hedgehog‑safe" mowers.Study co‑author Anne Berger of Germany’s Leibniz Institute for Zoo and Wildlife Research warned that injuries from robotic mowers place an "enormous burden" on animal‑care centres, with many victims discovered days or weeks after the incident, enduring prolonged suffering.German law already protects hedgehogs, imposing fines of up to €65,000 for illegal trapping, injury, or killing. Several cities—including Cologne, Leipzig and Munich—have already outlawed night‑time mower operation. However, a recent attempt by the Greens to enact a statewide ban in Bavaria was rejected.